Insilico Medicine.
American biotechnology company
- Reports this week
- 1
- Active events
- 2
- Connections
- 47
What's happening
Active this week
-
Insilico Medicine and Harvard Medical School have begun a collaboration focused on AI-driven drug discovery.Some support2 reports1 development inside
-
Insilico Medicine developed PLSI for the Grok Bot platform in collaboration with David Sinclair, a researcher from Harvard Medical School.Some support1 report
Earlier this month
One to three months ago
-
Insilico Medicine, Buck Institute for Research on Aging, and Harvard Medical School have announced a collaboration on longevity research initiatives.Some support2 reports
-
Insilico Medicine is hosting a multi-center Phase III clinical trial for its drug Rentosertib at leading hospitals.Some support2 reports
-
CEO Alex Zhavoronkov predicts AI can revolutionize the field of drug discovery.Some support2 reports1 development inside
-
Insilico's AI platform developed rentosertib for IPF, and CEO Alex Zhavoronkov presented findings at Sorbonne.Some support1 report
-
Insilico Medicine, a company, is based in Cambridge, Massachusetts.Some support4 reports
-
Morgan Stanley is compiling indexes for MSCI, leading to the inclusion of a company in the MSCI Global Small Cap Indexes.Some support2 reports
-
Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.Some support1 report
-
Insilico Medicine and Hangzhou Tigermed Consulting Co., Ltd. announced a collaboration focused on R&D.Some support4 reports
-
State funding supports domestic EDA growth in China, while Insilico Medicine seeks to build a yuan fund.Some support1 report
-
Insilico Medicine announced a launch from Cambridge on August 14, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Insilico Medicine presented Phase 1 data for its ISM6331 drug candidate.Some support2 reports
-
Insilico Medicine and Bora formed a strategic alliance on July 14, 2026, to pioneer next-generation drug innovation.Some support2 reports
-
Insilico Medicine announced drug discovery collaborations with Eli Lilly and Servier.Some support2 reports
-
Insilico Medicine announced research findings from its headquarters in Cambridge, presenting at major medical conferences.Some support2 reports
-
Insilico Medicine and Takeda announced a strategic collaboration to advance drug candidates.Some support4 reports
-
Donghoon Lee has been appointed as the President and CEO of SK Biopharmaceuticals.Well supported3 reports
-
Human Longevity and Insilico Medicine announced a collaboration to develop foundation models for longevity science.Some support1 report1 development inside
-
Insilico Medicine is conducting a Phase I study in Australia, and Feng Ren serves as Co-CEO and Chief Scientific Officer.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Insilico Medicine this week
News at the entities that move Insilico Medicine most-
Harvard Medical School OperationalKseniia Petrova conducted cancer research and obtained samples in France for Harvard Medical School.Moves Insilico Medicine
-
MSCI StructuralMSCI rebalancing test affects Indian markets.Moves Insilico Medicine
-
Eli Lilly and Company OperationalMastercard, Eli Lilly, and Visa are noted as holdings within the Vanguard Morningstar Growth ETF (VUG).Moves Insilico Medicine
-
Johns Hopkins University OperationalResearchers published a working paper analyzing inflation surges in Europe and the US.Moves Insilico Medicine
-
Grok StructuralGrok was utilized during a military operation in Venezuela.Moves Insilico Medicine
Connections
The 31 strongest of 47, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Alex Zhavoronkov Structural
Alex Zhavoronkov serves as the Founder and Co-CEO of Insilico Medicine.
-
Feng Ren Structural
Feng Ren holds the critical leadership roles of Co-CEO and Chief Scientific Officer at Insilico Medicine.
-
Harvard Medical School Operational
Insilico Medicine and Harvard Medical School maintain an active, ongoing partnership focused on AI-driven drug discovery and longevity research.
-
Peking Union Medical College Hospital Structural
Insilico Medicine utilizes Peking Union Medical College Hospital as a site for its Phase III clinical trials for Rentosertib.
-
Grok Structural
Insilico Medicine developed PLSI, a component used in the Grok Bot platform.
-
Takeda Operational
Insilico Medicine and Takeda are engaged in a strategic partnership focused on leveraging AI platforms to co-develop drug candidates.
-
Eli Lilly and Company Operational
Insilico Medicine and Eli Lilly are engaged in a formal drug discovery collaboration.
-
Johns Hopkins University Operational
The two entities are actively collaborating on cutting-edge research focused on rare cancers.
Show all 31 connections
-
Chinese Academy of Medical Sciences Operational
The Chinese Academy of Medical Sciences is involved in leading the Phase III clinical trial for Insilico Medicine.
-
Shanghai Pulmonary Hospital Operational
The two entities are actively collaborating on a multi-center Phase III clinical study.
-
Servier Operational
The two companies are engaged in announced drug discovery collaborations.
-
Jue Wang Structural
Jue Wang serves as the Head of Global Business Development for Insilico Medicine.
-
Human Longevity Operational
The two companies are engaged in an active partnership, collaborating on foundation models for longevity science and sharing unique multi-omic and clinical datasets.
-
Buck Institute for Research on Aging Operational
The two entities actively collaborate on shared longevity research initiatives and studies.
-
FDA Transactional
Insilico Medicine is seeking a Fast Track review from the FDA for its candidate ISM6331.
-
Bora Operational
Insilico Medicine and Bora have formed a strategic alliance to pioneer next-generation drug innovation.
-
MSCI Structural
Insilico Medicine is formally included in the MSCI Global Small Cap Indexes, a classification made by MSCI.
-
University of Chicago Operational
The entities are engaged in a collaborative research partnership focused on rare cancer.
-
David Sinclair Operational
Insilico Medicine and David Sinclair have engaged in a collaboration.
-
Cambridge Shared context
Insilico Medicine is headquartered in Cambridge, Massachusetts.
-
Oxford Shared context
The company Insilico operates within the geographical and research context of Oxford, leveraging its ecosystem.
-
Hangzhou Shared context
Insilico Medicine leverages the operational context of Hangzhou for deepening clinical trials and R&D collaborations.
-
UBS Mentioned together
The two companies are being discussed in the context of the global longevity market size and growth.
-
Beijing Shared context
The company operates within the economic and geographic context of Beijing, China.
-
Sorbonne University Transactional
The entities collaborated on research findings which were presented at a conference.
-
European Society for Medical Oncology Shared context
Insilico Medicine presents drug candidate data within the context of the European Society for Medical Oncology.
-
Cambridge Shared context
Insilico Medicine operates from its headquarters in Cambridge, Massachusetts.
-
Massachusetts Shared context
Insilico Medicine operates from its headquarters located in Massachusetts, USA.
-
Shanghai Shared context
Insilico Medicine participated in a summit held in Shanghai.
-
American Thoracic Society Operational
Insilico Medicine presents its research findings at major medical conferences hosted by the American Thoracic Society.
-
Donghoon Lee Mentioned together
No evidence found linking the two entities in the provided timeline.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
1 eventSeptember 2026
5 events- Insilico Medicine and Harvard Medical School have begun a collaboration focused on AI-driven drug discovery.
- Insilico Medicine, Buck Institute for Research on Aging, and Harvard Medical School have announced a collaboration on longevity research initiatives.
- Insilico Medicine is hosting a multi-center Phase III clinical trial for its drug Rentosertib at leading hospitals.
- Insilico's AI platform developed rentosertib for IPF, and CEO Alex Zhavoronkov presented findings at Sorbonne.
- Insilico Medicine, a company, is based in Cambridge, Massachusetts.
Show 3 earlier months
August 2026
6 events- CEO Alex Zhavoronkov predicts AI can revolutionize the field of drug discovery.
- Morgan Stanley is compiling indexes for MSCI, leading to the inclusion of a company in the MSCI Global Small Cap Indexes.
- Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.
- Insilico Medicine and Hangzhou Tigermed Consulting Co., Ltd. announced a collaboration focused on R&D.
- State funding supports domestic EDA growth in China, while Insilico Medicine seeks to build a yuan fund.
- Insilico Medicine announced a launch from Cambridge on August 14, 2026.
July 2026
5 events- Insilico Medicine presented Phase 1 data for its ISM6331 drug candidate.
- Insilico Medicine and Bora formed a strategic alliance on July 14, 2026, to pioneer next-generation drug innovation.
- Insilico Medicine announced drug discovery collaborations with Eli Lilly and Servier.
- Insilico Medicine announced research findings from its headquarters in Cambridge, presenting at major medical conferences.
- Insilico Medicine and Takeda announced a strategic collaboration to advance drug candidates.
June 2026
3 events- Donghoon Lee has been appointed as the President and CEO of SK Biopharmaceuticals.
- Human Longevity and Insilico Medicine announced a collaboration to develop foundation models for longevity science.
- Insilico Medicine is conducting a Phase I study in Australia, and Feng Ren serves as Co-CEO and Chief Scientific Officer.